{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:54:34Z","timestamp":1751680474365,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma KK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12185-021-03149-z","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T19:08:51Z","timestamp":1618340931000},"page":"152-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids"],"prefix":"10.1007","volume":"114","author":[{"given":"Tze Fang","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Majewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7645-0989","authenticated-orcid":false,"given":"Yoshiaki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"3149_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","volume":"133","author":"N Cooper","year":"2006","unstructured":"Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133:364\u201374.","journal-title":"Br J Haematol"},{"key":"3149_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","volume":"27","author":"G Kistangari","year":"2013","unstructured":"Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27:495\u2013520.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3149_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-013-1370-4","volume":"98","author":"H Kashiwagi","year":"2013","unstructured":"Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24\u201333.","journal-title":"Int J Hematol"},{"key":"3149_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3949\/ccjm.78gr.10005","volume":"78","author":"K McCrae","year":"2011","unstructured":"McCrae K. Immune thrombocytopenia: no longer \u201cidiopathic.\u201d Cleve Clin J Med. 2011;78:358\u201373.","journal-title":"Cleve Clin J Med"},{"key":"3149_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-6-13","volume":"6","author":"SD Mathias","year":"2008","unstructured":"Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner T, et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes. 2008;6:13.","journal-title":"Health Qual Life Outcomes"},{"key":"3149_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12185-019-02790-z","volume":"111","author":"H Kashiwagi","year":"2020","unstructured":"Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Int J Hematol. 2020;111:329\u201351.","journal-title":"Int J Hematol"},{"key":"3149_CR7","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/bloodadvances.2020001446","volume":"4","author":"T Hato","year":"2020","unstructured":"Hato T, Shimada N, Kurata Y, Kuwana M, Fujimura K, Kashiwagi H, et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Adv. 2020;4:1648\u201355.","journal-title":"Blood Adv"},{"key":"3149_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393\u2013402.","journal-title":"Lancet"},{"key":"3149_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12185-013-1401-1","volume":"98","author":"S Katsutani","year":"2013","unstructured":"Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013;98:323\u201330.","journal-title":"Int J Hematol"},{"key":"3149_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","volume":"10","author":"Y Tomiyama","year":"2012","unstructured":"Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10:799\u2013806.","journal-title":"J Thromb Haemost"},{"key":"3149_CR11","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, Salama A, Socorro O, Portella M, Burgess P, et al. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130:2527\u201336.","journal-title":"Blood"},{"key":"3149_CR12","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood-2019-126000","volume":"134","author":"G Moulis","year":"2019","unstructured":"Moulis G, Rueter M, Lafaurie M, Lapeyre-Mestre M, Carmen investigators Group. Eltrombopag for immune thrombocytopenia adult patients in the real-life practice in France. Interim results of the elextra study. Blood. 2019;134:2372.","journal-title":"Blood"},{"key":"3149_CR13","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2019-128336","volume":"134","author":"H Nazaryan","year":"2019","unstructured":"Nazaryan H, Liu Y, Sirotich E, Duncan JM, Arnold DM. Second-line therapy for immune thrombocytopenia: real-world experience. Blood. 2019;134:2120.","journal-title":"Blood"},{"key":"3149_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","volume":"128","author":"A Cuker","year":"2016","unstructured":"Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128:1547\u201354.","journal-title":"Blood"},{"key":"3149_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MBC.0b013e32835fac99","volume":"24","author":"MD Tarantino","year":"2013","unstructured":"Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013;24:284\u201396.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3149_CR16","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00277-018-3367-9","volume":"97","author":"M Qu","year":"2018","unstructured":"Qu M, Liu Q, Zhao HG, Peng J, Ni H, Hou M, et al. Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. Ann Hematol. 2018;97:1701\u20136.","journal-title":"Ann Hematol"},{"key":"3149_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/2042098618769587","volume":"9","author":"JR Gonzalez-Porras","year":"2018","unstructured":"Gonzalez-Porras JR, Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf. 2018;9:263\u201385.","journal-title":"Ther Adv Drug Saf"},{"key":"3149_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/bjh.12169","volume":"160","author":"JB Bussel","year":"2013","unstructured":"Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Nl S. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013;160:538\u201346.","journal-title":"Br J Haematol"},{"key":"3149_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00134-002-1233-6","volume":"28","author":"EE Wade","year":"2002","unstructured":"Wade EE, Rebuck JA, Healey MA, Rogers FB. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon? Intensive Care Med. 2002;28:459\u201365.","journal-title":"Intensive Care Med"},{"key":"3149_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3109\/09537104.2014.880108","volume":"26","author":"E Binnetoglu","year":"2015","unstructured":"Binnetoglu E, Akbal E, Sen H, Gunes F, Erbag G, Asik M, et al. Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. Platelets. 2015;26:10\u20132.","journal-title":"Platelets"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03149-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T10:16:16Z","timestamp":1626948976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3149"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03149-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tze Fang Wong is the employee of Novartis KK, the manufacturer and retailer of eltrombopag. Renata Majewska is the employee of Creativ-Ceutical, which received funding from Novartis KK. Yoshiaki Tomiyama reports honoraria and speakers bureau fees from Novartis and Kyowa Kirin, and advisory role for Sysmex. Yoshiaki Tomiyama is an associate editor of International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}